Analysis of clinical and pathological characteristics of retroperitoneal paraganglioma and associated prognostic factors

被引:1
作者
Chun, Caipu [1 ,2 ,3 ]
Song, Linxie [1 ,2 ]
Xu, Guixuan [1 ,2 ]
Shi, Qi [1 ,2 ]
Li, Feng [1 ,2 ]
Jia, Xingyuan [1 ,2 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, 8 Workers Stadium South Rd, Beijing 100020, Peoples R China
[2] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, 8 Workers Stadium South Rd, Beijing 100020, Peoples R China
[3] Shihezi Univ, Affiliated Hosp 4, Dept Pathol, Akesu, Peoples R China
关键词
endovascular tumor embolus; metastasis and recurrence; modified GAPP grading; negative expression of SDHB and S-100; neuroendocrine neoplasm; prognosis; progression-free survival; retroperitoneal paraganglioma; MALIGNANT PHEOCHROMOCYTOMA; GENETICS; DIAGNOSIS;
D O I
10.1002/jso.27681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: The aim of this study is to explore the long-term prognostic risk factors associated with patients diagnosed with retroperitoneal paraganglioma (RPGL) and examine their clinical and pathological characteristics. Methods: Expressions of biomarkers were identified using immunohistochemistry (IHC) and case databases were retrospectively searched. Survival analysis was performed using Kaplan-Meier and Cox risk regression to identify the factors that influence the postoperative progression-free survival of patients with RPGL. Results: A total of 105 patients, most of whom had tumors situated in the paraaortic region, and whose average tumor size was 8.6 cm, were enrolled in this study. The average follow-up duration was 51 months, with a mortality rate of 19% and a recurrence and metastasis rate of 41.9%. Tumors were assessed using the modified Grading system for Adrenal Pheochromocytoma and Paraganglioma (GAPP), and SDHB, S-100, and Ki-67 were stained using IHC in all cases. Out of the total cases examined, negative in SDHB expression were observed in 18.1% of cases, S-100 expression was negative in 36.2% of cases, and endovascular tumor enboluswas present in approximately 25.7% of cases. The results of the univariate analysis indicated that several factors significantly influenced the progression-free survival of patients with PGL as follow: maximum tumor diameter (>5.5 cm), tumor morphological features, tumor grading (modified GAPP score > 6), SDHB negative, S-100 negative, and expression of proliferation index Ki-67 (>3%) (X-2 = 4.217-27.420, p < 0.05). The results of the multivariate analysis indicated that negative of S-100 (p = 0.021) and SDHB (p = 0.038), as well as intravascular tumor thrombus (p = 0.047) expression were independent risk factors for progression-free survival in patients. Conclusion: RPGL is characterized by diverse biological features and an elevated susceptibility to both recurrence and metastasis. Both SDHB and S-100 can be employed as traditional IHC indicators to predict the metastatic risk of PGL, whereas the tumor histomorphology-endovascular tumor enbolus assists in determining the metastasis risk of RPGL.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 25 条
  • [1] Phaeochromocytomas and Paragangliomas: A Difference in Disease Behaviour and Clinical Outcomes
    Abdel-Aziz, Tarek Ezzat
    Prete, Francesco
    Conway, Gerard
    Gaze, Mark
    Bomanji, Jamshed
    Bouloux, Pierre
    Khoo, Bernard
    Caplin, Martyn
    Mushtaq, Imran
    Smart, James
    Kurzawinski, Tom R.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (05) : 486 - 491
  • [2] SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma
    Assadipour, Yasmine
    Sadowski, Samira M.
    Alimchandani, Meghna
    Quezado, Martha
    Steinberg, Seth M.
    Nilubol, Naris
    Patel, Dhaval
    Prodanov, Tamara
    Pacak, Karel
    Kebebew, Electron
    [J]. SURGERY, 2017, 161 (01) : 230 - 237
  • [3] Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators
    Ayala-Ramirez, Montserrat
    Feng, Lei
    Johnson, Marcella M.
    Ejaz, Shamim
    Habra, Mouhammed Amir
    Rich, Thereasa
    Busaidy, Naifa
    Cote, Gilbert J.
    Perrier, Nancy
    Phan, Alexandria
    Patel, Shreyaskumar
    Waguespack, Steven
    Jimenez, Camilo
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) : 717 - 725
  • [4] Clinical manifestations of paraganglioma syndromes types 1-5
    Benn, Diana E.
    Robinson, Bruce G.
    Clifton-Bligh, Roderick J.
    [J]. ENDOCRINE-RELATED CANCER, 2015, 22 (04) : T91 - T103
  • [5] An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma
    Buffet, Alexandre
    Burnichon, Nelly
    Favier, Judith
    Gimenez-Roqueplo, Anne-Paule
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 34 (02)
  • [6] Long-term outcomes of abdominal paraganglioma
    Choi, Hye Ryeon
    Yap, Zeng
    Choi, Soon Min
    Choi, Sun Hyung
    Kim, Jin Kyong
    Lee, Cho Rok
    Lee, Jandee
    Jeong, Jong Ju
    Nam, Kee-Hyun
    Chung, Woong Youn
    Kang, Sang-Wook
    [J]. ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 99 (06) : 315 - 319
  • [7] Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once!
    Dahia, Patricia L. M.
    [J]. CANCER CELL, 2017, 31 (02) : 159 - 161
  • [8] Malignant pheochromocytoma: new malignancy criteria
    de Wailly, Pierre
    Oragano, Luigi
    Rade, Francois
    Beaulieu, Anthony
    Arnault, Vincent
    Levillain, Pierre
    Kraimps, Jean Louis
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2012, 397 (02) : 239 - 246
  • [9] Simultaneous Occurrence of Germline Mutations of SDHB and TP53 in a Patient with Metastatic Pheochromocytoma
    Gniado, Ewa
    Carracher, Colin P.
    Sharma, Sona
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (04) : 991 - 995
  • [10] Malignant pheochromocytoma and paraganglioma: A population level analysis of long-term survival over two decades
    Goffredo, Paolo
    Sosa, Julie A.
    Roman, Sanziana A.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (06) : 659 - 664